Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ImmunityBio (IBRX) Treasury Shares (2016 - 2025)

ImmunityBio (IBRX) has disclosed Treasury Shares for 11 consecutive years, with $163800.0 as the latest value for Q4 2025.

  • On a quarterly basis, Treasury Shares changed 0.0% to $163800.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $163800.0, a 0.0% change, with the full-year FY2025 number at $163800.0, changed 0.0% from a year prior.
  • Treasury Shares was $163800.0 for Q4 2025 at ImmunityBio, roughly flat from $163800.0 in the prior quarter.
  • In the past five years, Treasury Shares ranged from a high of $163800.0 in Q1 2021 to a low of $163800.0 in Q1 2021.
  • A 5-year average of $163800.0 and a median of $163800.0 in 2021 define the central range for Treasury Shares.
  • Biggest YoY gain for Treasury Shares was 0.0% in 2021; the steepest drop was 85.14% in 2021.
  • ImmunityBio's Treasury Shares stood at $163800.0 in 2021, then changed by 0.0% to $163800.0 in 2022, then changed by 0.0% to $163800.0 in 2023, then changed by 0.0% to $163800.0 in 2024, then changed by 0.0% to $163800.0 in 2025.
  • Per Business Quant, the three most recent readings for IBRX's Treasury Shares are $163800.0 (Q4 2025), $163800.0 (Q3 2025), and $163800.0 (Q2 2025).